BioMarin Pharmaceuticals
BMRN
436 hedge funds and large institutions have $11.7B invested in BioMarin Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 35 funds opening new positions, 171 increasing their positions, 161 reducing their positions, and 79 closing their positions.
6% more repeat investments, than reductions
Existing positions increased: 171 | Existing positions reduced: 161
2.59% less ownership
Funds ownership: 99.53% → 96.93% (-2.6%)
10% less funds holding
Funds holding: 482 → 436 (-46)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
23% less capital invested
Capital invested by funds: $15.3B → $11.7B (-$3.53B)
27% less call options, than puts
Call options by funds: $81.3M | Put options by funds: $112M
56% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 79
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital Research Global Investors
Los Angeles,
California
|
+$155M |
| 2 |
Primecap Management
Pasadena,
California
|
+$67.7M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$58.9M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$45.3M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$40.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
-$134M |
| 2 |
Jennison Associates
New York
|
-$86M |
| 3 |
WRF
Waddell & Reed Financial
Overland Park,
Kansas
|
-$65.3M |
| 4 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$58.9M |
| 5 |
Neuberger Berman Group
New York
|
-$56.7M |
BMRN Hedge Fund Activity: Q3 2019 in Review
436 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q3 2019, worth a combined $11.7B — down 23% from $15.3B a quarter earlier.
Sellers outnumbered buyers: 79 funds closed out of BMRN and 35 opened new positions — a net loss of 44 holders — while 161 trimmed existing stakes and 171 added.
The largest buyer was Capital Research Global Investors, adding an estimated $155M. The largest seller was Nuveen, cutting an estimated $134M.
- 436 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q3 2019, down from 482 in Q2 2019.
- Funds reported $11.7B of BioMarin Pharmaceuticals stock for Q3 2019, down 23% quarter-over-quarter.
- 35 funds opened new BioMarin Pharmaceuticals positions in Q3 2019 and 79 closed out, a net change of -44 holders.
- The largest BioMarin Pharmaceuticals buyer in Q3 2019 was Capital Research Global Investors, an estimated $155M added.
- The largest BioMarin Pharmaceuticals seller in Q3 2019 was Nuveen, an estimated $134M sold.
Based on aggregated 13F filings for Q3 2019.